Schütz H - Search Results

1

Group-by-Treatment Interaction Effects in Comparative Bioavailability Studies.

Schütz H, Burger DA, Cobo E, Dubins DD, Farkás T, Labes D, Lang B, Ocaña J, Ring A, Shitova A, Stus V, Tomashevskiy M. Schütz H, et al. AAPS J. 2024 Apr 17;26(3):50. doi: 10.1208/s12248-024-00921-x. AAPS J. 2024. PMID: 38632178

2

Reference datasets for 2-treatment, 2-sequence, 2-period bioequivalence studies.

Schütz H, Labes D, Fuglsang A. Schütz H, et al. AAPS J. 2014 Nov;16(6):1292-7. doi: 10.1208/s12248-014-9661-0. Epub 2014 Sep 12. AAPS J. 2014. PMID: 25212768 Free PMC article.

3

Reference datasets for bioequivalence trials in a two-group parallel design.

Fuglsang A, Schütz H, Labes D. Fuglsang A, et al. Among authors: schutz h. AAPS J. 2015 Mar;17(2):400-4. doi: 10.1208/s12248-014-9704-6. Epub 2014 Dec 9. AAPS J. 2015. PMID: 25488055 Free PMC article.

4

Inflation of Type I Error in the Evaluation of Scaled Average Bioequivalence, and a Method for its Control.

Labes D, Schütz H. Labes D, et al. Among authors: schutz h. Pharm Res. 2016 Nov;33(11):2805-14. doi: 10.1007/s11095-016-2006-1. Epub 2016 Aug 1. Pharm Res. 2016. PMID: 27480875

5

Sample size determination in bioequivalence studies using statistical assurance.

Ring A, Lang B, Kazaroho C, Labes D, Schall R, Schütz H. Ring A, et al. Among authors: schutz h. Br J Clin Pharmacol. 2019 Oct;85(10):2369-2377. doi: 10.1111/bcp.14055. Epub 2019 Aug 13. Br J Clin Pharmacol. 2019. PMID: 31276603 Free PMC article.

6

Reference Datasets for Studies in a Replicate Design Intended for Average Bioequivalence with Expanding Limits.

Schütz H, Labes D, Tomashevskiy M, la Parra MG, Shitova A, Fuglsang A. Schütz H, et al. AAPS J. 2020 Feb 7;22(2):44. doi: 10.1208/s12248-020-0427-6. AAPS J. 2020. PMID: 32034551

7

An iterative method to protect the type I error rate in bioequivalence studies under two-stage adaptive 2×2 crossover designs.

Molins E, Labes D, Schütz H, Cobo E, Ocaña J. Molins E, et al. Among authors: schutz h. Biom J. 2021 Jan;63(1):122-133. doi: 10.1002/bimj.201900388. Epub 2020 Oct 1. Biom J. 2021. PMID: 33000873

8

Assessing goodness-of-fit for evaluation of dose-proportionality.

Wolfsegger MJ, Bauer A, Labes D, Schütz H, Vonk R, Lang B, Lehr S, Jaki TF, Engl W, Hale MD. Wolfsegger MJ, et al. Among authors: schutz h. Pharm Stat. 2021 Mar;20(2):272-281. doi: 10.1002/pst.2074. Epub 2020 Oct 15. Pharm Stat. 2021. PMID: 33063443

9

Critical Remarks on Reference-Scaled Average Bioequivalence.

Schütz H, Labes D, Wolfsegger MJ. Schütz H, et al. J Pharm Pharm Sci. 2022;25:285-296. doi: 10.18433/jpps32892. J Pharm Pharm Sci. 2022. PMID: 36112990 Free article.

10

Correction: Group-by-Treatment Interaction Effects in Comparative Bioavailability Studies.

Schütz H, Burger DA, Cobo E, Dubins DD, Farkás T, Labes D, Lang B, Ocaña J, Ring A, Shitova A, Stus V, Tomashevskiy M. Schütz H, et al. AAPS J. 2024 May 6;26(3):58. doi: 10.1208/s12248-024-00927-5. AAPS J. 2024. PMID: 38710975 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

340 results

Search Page

Filters